CL2020002102A1 - Inhibidores de la vía de jak1 para el tratamiento de trastornos relacionados con citoquinas. - Google Patents

Inhibidores de la vía de jak1 para el tratamiento de trastornos relacionados con citoquinas.

Info

Publication number
CL2020002102A1
CL2020002102A1 CL2020002102A CL2020002102A CL2020002102A1 CL 2020002102 A1 CL2020002102 A1 CL 2020002102A1 CL 2020002102 A CL2020002102 A CL 2020002102A CL 2020002102 A CL2020002102 A CL 2020002102A CL 2020002102 A1 CL2020002102 A1 CL 2020002102A1
Authority
CL
Chile
Prior art keywords
inhibitors
treatment
cytokine
related disorders
jak1 pathway
Prior art date
Application number
CL2020002102A
Other languages
English (en)
Inventor
Montgomery Michael O'neill
Ahmad Naim
Susan Snodgrass
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2020002102A1 publication Critical patent/CL2020002102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta descripción se refiere a los inhibidores de la vía de JAK1 y su uso en el tratamiento de enfermedades o trastornos relacionados con citoquinas como el síndrome de liberación de citoquinas (CRS), la linfohistiocitosis hemofagocítica (HLH), el síndrome de activación de macrófagos (MAS) y el síndrome de encefalopatía relacionada con células T CAR (CRES).
CL2020002102A 2018-02-16 2020-08-14 Inhibidores de la vía de jak1 para el tratamiento de trastornos relacionados con citoquinas. CL2020002102A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862710446P 2018-02-16 2018-02-16
US201862631825P 2018-02-18 2018-02-18

Publications (1)

Publication Number Publication Date
CL2020002102A1 true CL2020002102A1 (es) 2021-01-29

Family

ID=65529906

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002102A CL2020002102A1 (es) 2018-02-16 2020-08-14 Inhibidores de la vía de jak1 para el tratamiento de trastornos relacionados con citoquinas.

Country Status (20)

Country Link
US (4) US11103510B2 (es)
EP (1) EP3752146A1 (es)
JP (3) JP7736431B2 (es)
KR (3) KR102830476B1 (es)
CN (4) CN111936135A (es)
AU (2) AU2019221667B2 (es)
BR (3) BR122023022247A2 (es)
CA (1) CA3091339A1 (es)
CL (1) CL2020002102A1 (es)
CO (1) CO2020011388A2 (es)
EC (1) ECSP20057643A (es)
IL (3) IL311485B1 (es)
MA (1) MA51829A (es)
MX (2) MX2020008521A (es)
PE (1) PE20212186A1 (es)
PH (1) PH12020551251A1 (es)
SG (1) SG11202007805SA (es)
TW (1) TWI799513B (es)
UA (1) UA127519C2 (es)
WO (1) WO2019161098A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013337824B2 (en) 2012-11-01 2018-03-08 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
SMT202100040T1 (it) 2013-05-17 2021-03-15 Incyte Corp Derivati di bipirazolo come inibitori di jak
KR102830476B1 (ko) 2018-02-16 2025-07-08 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
IL282643B2 (en) 2018-10-31 2025-08-01 Incyte Corp A selective jak1 inhibitor for use in a method of treating hematological disease
IL285999B2 (en) 2019-03-05 2026-01-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
BR112022001418A2 (pt) * 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
AU2021396231A1 (en) * 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
JP2022090856A (ja) * 2020-12-08 2022-06-20 ソニーセミコンダクタソリューションズ株式会社 測距装置、および測距方法、並びにプログラム
SI4333840T1 (sl) * 2021-05-03 2026-01-30 Incyte Corporation Zaviralci poti jak1 za zdravljenje pruriga nodularisa
CN117858709A (zh) * 2022-08-08 2024-04-09 石药集团中奇制药技术（石家庄）有限公司 一种含有三环杂芳基的化合物的用途
CN120053657B (zh) * 2025-02-28 2025-09-09 东莞市第八人民医院（东莞市儿童医院） 用于治疗aplaid的药物及药物组合物
CN121227629A (zh) * 2025-12-01 2025-12-30 暨南大学 经调控处理的γδT细胞及其干预性调控方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP5119154B2 (ja) 2005-09-22 2013-01-16 インサイト・コーポレイション Ｊａｎｕｓキナーゼの四環系阻害剤
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2569528T3 (es) 2007-11-16 2016-05-11 Incyte Holdings Corporation 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
PL2288610T3 (pl) 2008-03-11 2017-12-29 Incyte Holdings Corporation Azetydynowe i cyklobutanowe pochodne jako inhibitory jak
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
TWI665200B (zh) 2009-01-15 2019-07-11 英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
CN105541847B (zh) 2009-10-09 2019-08-16 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
CN102844317B (zh) 2010-02-18 2015-06-03 因西特公司 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
EP3050882B1 (en) * 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PH12012502046A1 (en) 2010-04-14 2017-07-26 Array Biopharma Inc 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AU2012313094B2 (en) 2011-09-22 2017-02-02 Intervet International B.V. Pyrazole carboxamides as janus kinase inhibitors
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AU2013337824B2 (en) 2012-11-01 2018-03-08 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
WO2014184328A1 (en) 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SMT202100040T1 (it) 2013-05-17 2021-03-15 Incyte Corp Derivati di bipirazolo come inibitori di jak
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3035966A1 (en) 2013-08-20 2016-06-29 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
CA2926361A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
CA2940659C (en) * 2014-02-28 2023-01-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
JP2017514832A (ja) 2014-04-30 2017-06-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１抑制剤を調製する方法及びその新しい形態
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
HRP20192009T1 (hr) 2014-12-16 2020-02-07 Novartis Ag Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
EP3384294B1 (en) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
MA44486A (fr) * 2016-03-22 2019-01-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
US20190336504A1 (en) * 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
KR102830476B1 (ko) 2018-02-16 2025-07-08 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
CN115836065B (zh) 2020-06-02 2025-07-01 因赛特公司 制备jak1抑制剂的方法
TW202237125A (zh) 2020-12-04 2022-10-01 美商英塞特公司 用於治療皮膚疾病之jak抑制劑與維生素d類似物
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
SI4333840T1 (sl) 2021-05-03 2026-01-30 Incyte Corporation Zaviralci poti jak1 za zdravljenje pruriga nodularisa

Also Published As

Publication number Publication date
IL311485B1 (en) 2026-01-01
ECSP20057643A (es) 2020-12-31
JP2024023213A (ja) 2024-02-21
SG11202007805SA (en) 2020-09-29
IL325285A (en) 2026-02-01
US20250367202A1 (en) 2025-12-04
KR20240158365A (ko) 2024-11-04
KR102830476B1 (ko) 2025-07-08
US11103510B2 (en) 2021-08-31
JP2026048833A (ja) 2026-03-17
CN118490690A (zh) 2024-08-16
BR112020016628A2 (pt) 2020-12-15
AU2024204891A1 (en) 2024-08-01
IL276725A (en) 2020-09-30
BR122023022189A2 (pt) 2024-02-20
BR122023022247A2 (pt) 2024-02-20
AU2019221667B2 (en) 2024-08-08
CN118557580A (zh) 2024-08-30
AU2019221667A1 (en) 2020-10-01
CN119386019A (zh) 2025-02-07
TW202000203A (zh) 2020-01-01
IL276725B1 (en) 2024-05-01
EP3752146A1 (en) 2020-12-23
IL311485A (en) 2024-05-01
US11833152B2 (en) 2023-12-05
JP7736431B2 (ja) 2025-09-09
TW202342026A (zh) 2023-11-01
TWI799513B (zh) 2023-04-21
CA3091339A1 (en) 2019-08-22
PE20212186A1 (es) 2021-11-11
KR20200128043A (ko) 2020-11-11
MA51829A (fr) 2020-12-23
US20240156818A1 (en) 2024-05-16
CN111936135A (zh) 2020-11-13
UA127519C2 (uk) 2023-09-20
PH12020551251A1 (en) 2021-05-17
US12336998B2 (en) 2025-06-24
US20190255053A1 (en) 2019-08-22
WO2019161098A1 (en) 2019-08-22
KR102925957B1 (ko) 2026-02-11
US20220040187A1 (en) 2022-02-10
MX2023003392A (es) 2023-06-16
JP2021513981A (ja) 2021-06-03
MX2020008521A (es) 2020-12-03
KR20240157777A (ko) 2024-11-01
IL276725B2 (en) 2024-09-01
CO2020011388A2 (es) 2020-12-10

Similar Documents

Publication Publication Date Title
ECSP20057643A (es) Inhibidores de la vía de jak1 para el tratamiento de trastornos relacionados con citoquinas
CO2021001530A2 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
MX2018014927A (es) Agonista del receptor de glucocorticoides e inmumoconjugados del mismo.
ECSP19070336A (es) Arn terapéutico
UY38806A (es) Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
AR112969A1 (es) Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
MX2021005593A (es) Miméticos de interleucina dividida y sus usos.
MX2015003140A (es) Formulaciones de enzalutamida.
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CR20140460A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
MX2021004679A (es) Profarmacos antivirales y nanoformulaciones de las mismas.
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2024000882A (es) Agonistas del receptor de il12 y métodos para su uso.
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
NI201900080A (es) Moduladores del receptor de estrógeno